Samantha has been working with ctDNA applications for monitoring of treatment response, identifying markers of resistance, and matching drugs to actionable targets.
Are you new to ctDNA testing strategies? Fear not! With this walk-through, we will guide you through some high-level concepts to help orient yourself in the current clinical landscape.
In this briefing, we walk you through a step-by-step process of the resources you can access to assess variant pathogenicity and actionability.
Vessel Tutorial - Understanding liquid biopsy results is highly dependent on tumor fraction of the cell-free DNA sample. Without information about ctDNA content from plasma, variant allele frequencies and uninformative testing results are very difficult to interpret.
Brief Synopsis For this Briefing, we asked Prof. Ellen Heitzer and Georgios Vlachos from the Institute of Human Genetics, Medical University of...
Tissue and circulating tumor DNA testing can detect cancer alterations, but discrepancies in results can impact treatment decisions. This briefing discusses the basics and presents case studies.